1.Recombinant yeast-cell microcapsules carrying the DNA vaccine against enterotoxigenic Escherichia coli.
Xiafang ZHAO ; Lihong DU ; Baoxia MA ; Shaona JIA ; Yufei LIU ; Yufei ZHU ; Xiaotao MA ; Xiaojun YANG ; Kun XU
Chinese Journal of Biotechnology 2025;41(6):2388-2404
The enterotoxigenic Escherichia coli (ETEC) infection is a major factor restricting the development of animal husbandry. However, the abuse of antibiotics will lead to the antibiotic residues and emergence of antibiotic-resistant bacteria. The existing vaccines face challenges in stimulating intestinal immunity, demonstrating limited prevention effects. Therefore, it is indispensable to develop a new vaccine that is safe and suitable as a feed additive to activate intestinal immunity. This study constructed yeast-cell microcapsules (YCM) carrying the DNA vaccine against ETEC by genetic engineering. Furthermore, animal experiments were carried out to explore the regulatory effects of feeding YCM on the intestinal immune system and intestinal microbiota. Saccharomyces cerevisiae was selected as the oral delivery vehicle (microcapsules) of the DNA vaccine. The codon-optimized nucleic acid sequence of K88, the main antigen of mammal-derived ETEC, was synthesized, and the yeast shuttle vector containing the corresponding DNA vaccine expression cassette was constructed by DNA recombination. The recombinant strain of YCM was prepared by transforming JMY1. Additionally, the characteristics of the YCM strain and its feasibility as an oral vaccine were comprehensively evaluated by the fluorescence reporter assay, gastrointestinal fluid tolerance assay, intestinal epithelial cell adhesion assay, intestinal retention assessment, antiserum detection, and intestinal microbiota detection. The experimental results showed that the DNA vaccine expression cassette was expressed in mammals, and the recombinant strain of YCM could tolerate up to 8 hours of gastrointestinal fluid digestion and had good adhesion to intestinal epithelial cells. The results of mouse feeding experiments indicated that the recombinant strain of YCM could stay in the intestinal tract for at least two weeks, and the DNA vaccine expression cassette carried by YCM entered the intestinal immune system and triggered an immune response to induce the production of specific antibodies. Moreover, feeding YCM recombinant bacteria also improved the abundance of gut microbiota in mice, demonstrating a positive effect in regulating intestinal flora. In summary, we prepared the recombinant strain of YCM carrying the DNA vaccine against ETEC and comprehensively evaluated its characteristics and feasibility as an oral vaccine. Feeding the recombinant YCM could induce specific immune responses and regulate intestinal microbiota. The findings provide a reference for the immunoprevention of ETEC-related animal diseases.
Animals
;
Enterotoxigenic Escherichia coli/genetics*
;
Saccharomyces cerevisiae/metabolism*
;
Vaccines, DNA/genetics*
;
Mice
;
Escherichia coli Infections/immunology*
;
Escherichia coli Vaccines/genetics*
;
Capsules
;
Mice, Inbred BALB C
;
Female
2.Preparation and immunogenicity evaluation of ferritin nanoparticles conjugated with African swine fever virus p30 protein.
Yue ZHANG ; Yi RU ; Rongzeng HAO ; Yang YANG ; Longhe ZHAO ; Yajun LI ; Rui YANG ; Bingzhou LU ; Haixue ZHENG
Chinese Journal of Biotechnology 2024;40(12):4509-4520
This study developed ferritin-based nanoparticles carrying the African swine fever virus (ASFV) p30 protein and evaluated their immunogenicity, aiming to provide an experimental basis for the research on nanoparticle vaccines against ASFV. Initially, the gene sequences encoding the p30 protein and SpyTag were fused and inserted into the pCold-I vector to create the pCold-p30 plasmid. The gene sequences encoding SpyCatcher and ferritin were fused and then inserted into the pET-28a(+) vector to produce the pET-F-np plasmid. Both plasmids were expressed in Escherichia coli upon induction. Subsequently, the affinity chromatography-purified p30 protein was conjugated with ferritin in vitro, and the p30-ferritin (F-p30) nanoparticles were purified by size-exclusion chromatography. The morphology and structural integrity of F-p30 nanoparticles were examined by a particle size analyzer and transmission electron microscopy. Mice were immunized with F-p30 nanoparticles, and the humoral and cellular immune responses were assessed. The results showed that F-p30 nanoparticles were successfully prepared, with the particle size of approximately 20 nm. F-p30 nanoparticles were efficiently internalized by bone marrow-derived dendritic cells (BMDCs) cells in vitro. Compared with the p30 protein alone, F-p30 nanoparticles induced elevated levels of specific antibodies and cytokines in mice and stimulated the proliferation of follicular helper T cell (TFH) and germinal center B cell (GCB) in lymph nodes as well as CD4+ and CD8+ T cells in the spleen. In conclusion, we successfully prepared F-p30 nanoparticles which significantly enhanced the immunogenicity of p30 protein, giving insights into the development of vaccines against ASFV.
Animals
;
Nanoparticles/chemistry*
;
Mice
;
African Swine Fever Virus/genetics*
;
Ferritins/chemistry*
;
Swine
;
Viral Vaccines/genetics*
;
African Swine Fever/immunology*
;
Mice, Inbred BALB C
;
Viral Proteins/genetics*
;
Escherichia coli/metabolism*
;
Dendritic Cells/immunology*
;
Immunogenicity, Vaccine
;
Antibodies, Viral/blood*
;
Female
;
Capsid Proteins/genetics*
3.Co-expression, purification and bioassay of three avian viral antigens.
Suling ZHANG ; Mengyue WANG ; Yanwei WANG ; Peng WU ; Wenqiang PANG ; Kegong TIAN
Chinese Journal of Biotechnology 2020;36(10):2066-2075
To achieve uniform soluble expression of multiple proteins in the same Escherichia coli strain, and simplify the process steps of antigen production in genetic engineering subunit multivalent vaccine, we co-expressed three avian virus proteins including the fowl adenovirus serotype 4 (FAdV-4) Fiber-2 protein, infectious bursal disease virus (IBDV) VP2 protein and egg-drop syndrome virus (EDSV) Fiber protein in E. coli BL21(DE3) cells after optimization of gene codon, promoter, and tandem expression order. The purified proteins were analyzed by Western blotting and agar gel precipitation (AGP). The content of the three proteins were well-proportioned after co-expression and the purity of the purified proteins were more than 80%. Western blotting analysis and AGP experiment results show that all the three co-expression proteins had immunoreactivity and antigenicity. It is the first time to achieve the three different avian virus antigens co-expression and co-purification, which simplified the process of antigen production and laid a foundation for the development of genetic engineering subunit multivalent vaccine.
Animals
;
Antigens, Viral/genetics*
;
Biological Assay
;
Chickens/immunology*
;
Escherichia coli/genetics*
;
Infectious bursal disease virus/immunology*
;
Poultry Diseases
;
Vaccines, Synthetic/isolation & purification*
;
Viral Structural Proteins/immunology*
;
Viral Vaccines/immunology*
4.Construction, expression and identification of chimeric foot-and-mouth disease virus-like particles.
Ronghuan LIU ; Huichen GUO ; Ping DU ; Hu DONG ; Mengnan GUO ; Shiqi SUN
Chinese Journal of Biotechnology 2020;36(7):1305-1313
To improve the specific recognition and presentation of virus-like particle (VLPs), and to develop immune-targeted VLPs vaccine, the gene fragment encoding OVA₂₅₇₋₂₆₄ peptide was inserted into the VP3 gene of foot-and-mouth disease virus (FMDV) between the 171th and 172th amino acids (aa) or 173th and 174th aa by reverse PCR. The recombinant proteins were expressed by using Escherichia coli and assembled into chimeric VLP (VLP(OVA)) in vitro after purification. The VLP(OVA) was measured by dynamic light scattering and transmission electron microscopy. The recombinant protein and the assembled VLPs were evaluated by Western blotting, enzyme-linked immunosorbent assay and laser scanning confocal microscopy to confirm the insertion of OVA₂₅₇₋₂₆₄ peptide into VP3 and its location. The results show that insertion of OVA₂₅₇₋₂₆₄ into the 173th and 174th aa of FMDV VP3 did not affect the assembly of VLPs. The VLP(OVA) in size was larger than VLPs, and the OVA₂₅₇₋₂₆₄ peptide was located on the surface of VLP(OVA).
Animals
;
Escherichia coli
;
genetics
;
Foot-and-Mouth Disease
;
virology
;
Foot-and-Mouth Disease Virus
;
genetics
;
Recombinant Proteins
;
genetics
;
metabolism
;
Vaccines, Virus-Like Particle
5.Construction and identification of HSV-1 vector vaccine carrying HIV-1 antigen.
Xiaofei ZHAO ; Jingxia GUO ; Xiaojuan LIU ; Zhenghai MA
Chinese Journal of Biotechnology 2015;31(3):384-393
To construct an HSV-1 vector vaccine carrying HIV-1 antigens, HIV-1 gp160, gag, protease and the expression elements were chained together, and then inserted into the internal inverted repeat sequence region of HSV-1 by bacterial artificial chromosome technology. Firstly, HIV-1 gp160 (including type B and C), gag and protease genes were cloned into pcDNA3 in series to generate the pcDNA/gBgp and pcDNA/gCgp, then the recombinant plasmids were transfected into 293FT cells, and HIV-1 antigen was detected from transfected cells by Western blotting. Then the expression cassettes from pcDNA/gBgp and pcDNA/gCgp, comprising HIV-1 antigen genes and expression elements, were cloned into pKO5/BN to generate the shuttle plasmids pKO5/BN/gBgp and pKO5/BN/gCgp. The shuttle plasmids were electroporated into E. coli cells that harbor an HSV-BAC, the recombinant bacteria were screened, and the recombinant DNA was extracted and transfected into Vero cells. The recombinant virus was purified through picking plaques, the virus' DNAs were identified by Southern blotting; HIV-1 antigen was detected from the recombinant HSV-1 infected cells by Western blotting, and the virus' replication competent was analyzed. As the results, gp160 and gag proteins were detected from 293FT cells transfected with pcDNA/gBgp and pcDNA/gCgp by Western blotting. The recombinant bacteria were generated from the E. coli electroporated with pKO5/BN/gBgp or pKO5/BN/gCgp. The recombinant HSV was purified from the Vero cells transfected with the recombinant DNA, the unique DNA fragment was detected from the genome of recombination HSV by Southern blotting; gp120 and gp41 were detected from the infected cells by Western blotting, and the recombinant HSV retained replication competent in mammalian cells. The results indicate that the recombinant HSV carrying HIV-1 gp160, gag and protease genes was generated, the virus retains replication competent in mammalian cells, and could be used as a replicated viral vector vaccine.
Animals
;
Cercopithecus aethiops
;
Chromosomes, Artificial, Bacterial
;
DNA, Recombinant
;
genetics
;
DNA, Viral
;
genetics
;
Escherichia coli
;
HIV Antigens
;
genetics
;
immunology
;
HIV Envelope Protein gp160
;
genetics
;
immunology
;
HIV Protease
;
genetics
;
immunology
;
Herpes Simplex Virus Vaccines
;
immunology
;
Herpesvirus 1, Human
;
physiology
;
Plasmids
;
Transfection
;
Vero Cells
;
Virus Replication
;
gag Gene Products, Human Immunodeficiency Virus
;
genetics
;
immunology
6.Cloning, expression and protective efficacy evaluation of radiation sensitive protein 23 (RAD23) from Schistosoma japonicum.
Changjian LI ; Min ZHANG ; Yang HONG ; Yanhui HAN ; Xiaodan CAO ; Hongxiao HAN ; Zhiqiang FU ; Chuangang ZHU ; Ke LU ; Hao LI ; Jiaojiao LIN
Chinese Journal of Biotechnology 2014;30(11):1669-1678
Radiation sensitive protein 23 (RAD23) is a nucleotide excision repair (NER) protein that plays an important role in Ubiquitin-proteasome pathway (UPP). Schistosoma japonicum radiation sensitive protein23 (SjRAD23) cDNA sequences were amplified by PCR and cloned into pET28a (+) vector to construct recombinant expression plasmid pET28a(+)-SjRAD23. The recombinant protein was expressed as both inclusion bodies and the supernatant in Escherichia coli BL21 (DE3) cell. Immunofluorescence observation shows that SjRAD23 was mainly distributed on the tegument surface of the worms. ELISA assay reveals that specific IgG, IgG1 and IgG2a antibodies could be detected in the sera of rSjRAD23 immunized mice. Western blotting analysis shows that the recombinant SjRAD23 could be recognized by serum specific to soluble adult worm antigen of S. japonicum. BALB/c mice vaccinated with rSjRAD23 combined with 206 adjuvant revealed 35.94% worm reduction and 40.59% liver egg reduction when compared with that of the adjuvant control
Animals
;
Antibodies, Helminth
;
blood
;
Blotting, Western
;
Cloning, Molecular
;
DNA Repair Enzymes
;
genetics
;
metabolism
;
DNA, Complementary
;
Enzyme-Linked Immunosorbent Assay
;
Escherichia coli
;
Genetic Vectors
;
Helminth Proteins
;
genetics
;
immunology
;
Immunoglobulin G
;
blood
;
Mice
;
Mice, Inbred BALB C
;
Recombinant Proteins
;
genetics
;
immunology
;
Schistosoma japonicum
;
genetics
;
metabolism
;
Schistosomiasis japonica
;
prevention & control
;
Vaccines
;
immunology
7.Positive effects of porcine IL-2 and IL-4 on virus-specific immune responses induced by the porcine reproductive and respiratory syndrome virus (PRRSV) ORF5 DNA vaccine in swine.
Deyuan TANG ; Jian LIU ; Chunyan LI ; Hua ZHANG ; Ping MA ; Xianfeng LUO ; Zhiyong ZENG ; Nining HONG ; Xia LIU ; Bin WANG ; Feng WANG ; Zhenlei GAN ; Fei HAO
Journal of Veterinary Science 2014;15(1):99-109
The purpose of this study was to investigate the effects of porcine interleukin (IL)-2 and IL-4 genes on enhancing the immunogenicity of a porcine reproductive and respiratory syndrome virus ORF5 DNA vaccine in piglets. Eukaryotic expression plasmids pcDNA-ORF5, pcDNA-IL-2, and pcDNA-IL-4 were constructed and then expressed in Marc-145 cells. The effects of these genes were detected using an indirect immunofluorescent assay and reverse transcription polymerase chain reaction (RT-PCR). Characteristic fluorescence was observed at different times after pcDNA-ORF5 was expressed in the Marc-145 cells, and PCR products corresponding to ORF5, IL-2, and IL-4 genes were detected at 48 h. Based on these data, healthy piglets were injected intramuscularly with different combinations of the purified plasmids: pcDNA-ORF5 alone, pcDNA-ORF5 + pcDNA-IL-2, pcDNA-ORF5 + pcDNA-IL-4, and pcDNA-ORF5 + pcDNAIL-4 + pcDNA-IL-2. The ensuing humoral immune responses, percentages of CD4+ and CD8+ T lymphocytes, proliferation indices, and interferon-gamma expression were analyzed. Results revealed that the piglets co-immunized with pcDNA-ORF5 + pcDNA-IL-4 + pcDNA-IL-2 plasmids developed significantly higher antibody titers and neutralizing antibody levels, had significantly increased levels of specific T lymphocyte proliferation, elevated percentages of CD4+ and CD8+ T lymphocytes, and significantly higher IFN-gamma production than the other inoculated pigs (p < 0.05).
Animals
;
Cell Line
;
Escherichia coli/genetics
;
Haplorhini
;
Immunity, Cellular
;
Interleukin-2/genetics/*metabolism
;
Interleukin-4/genetics/*metabolism
;
Neutralization Tests/veterinary
;
Plasmids
;
Porcine Reproductive and Respiratory Syndrome/*prevention & control
;
Porcine respiratory and reproductive syndrome virus/*immunology
;
Recombinant Proteins/genetics/metabolism
;
Swine
;
Vaccines, DNA/immunology
;
Viral Envelope Proteins/*genetics/metabolism
;
Viral Vaccines/*immunology
8.Investigation of a special neutralizing epitope of HEV E2s.
Min YOU ; Lu XIN ; Yi YANG ; Xiao ZHANG ; Yingwei CHEN ; Hai YU ; Shaowei LI ; Jun ZHANG ; Zhiqiang AN ; Wenxin LUO ; Ningshao XIA
Protein & Cell 2014;5(12):950-953
Antibodies, Monoclonal
;
chemistry
;
immunology
;
Antigens, Viral
;
chemistry
;
genetics
;
immunology
;
Binding Sites
;
Capsid Proteins
;
chemistry
;
genetics
;
immunology
;
Epitopes
;
chemistry
;
genetics
;
immunology
;
Escherichia coli
;
genetics
;
metabolism
;
Gene Expression
;
Hepatitis E
;
immunology
;
prevention & control
;
virology
;
Hepatitis E virus
;
chemistry
;
immunology
;
Humans
;
Molecular Docking Simulation
;
Mutagenesis, Site-Directed
;
Peptide Mapping
;
Protein Binding
;
Recombinant Proteins
;
chemistry
;
genetics
;
immunology
;
Viral Hepatitis Vaccines
;
administration & dosage
;
biosynthesis
9.Study on immunogenicity elicited by a recombinant vaccine of rBCG-Rv3133c to fight against dormancy Mycobacterium tuberculosis.
Yihao DENG ; Hongyun HE ; Bensi ZHANG
Journal of Biomedical Engineering 2013;30(4):817-821
To obtain a vaccine to defend from dormancy Mycobacterium tuberculosis, we constructed the recombinant Bacilli Calmette-Guérin (BCG) vaccine with Rv3133c encoding dormancy-correlated transcriptional regulatory protein DosR in Mycobacterium tuberculosis as a target gene, and evaluated its immunogenicity in BALB/c mice. In this study, we constructed the recombinant plasmids of rpMV361-Rv3133c using gene colon technology. We then transformed BCG strains with above-mentioned plasmids to obtain recombinant vaccine of rBCG-Rv3133c. We used the rBCG strains successfully constructed to vaccinate in BALB/c mice. 30d and 180d after immunization, the specific antibody titers were determined to investigate humoral responses induced by recombinant vaccine. We detected changes of splenocyte subsets of CD4+T, CD8+ T cells and cytokine of IFN-gamma secreted by splenocytes for evaluation of cellular immune responses. The results showed that the rBCG-Rv3133c was able to induce higher levels of antibody titer, stronger proliferative responses and higher IFN-gamma production comparing with BCG vaccine. The results also suggested that this recombinant vaccine was a more efficacious tuberculosis vaccine for further study.
Animals
;
Antibodies, Bacterial
;
blood
;
Antigens, Bacterial
;
genetics
;
immunology
;
BCG Vaccine
;
immunology
;
Bacterial Proteins
;
genetics
;
immunology
;
Escherichia coli
;
genetics
;
metabolism
;
Interferon-gamma
;
immunology
;
Mice
;
Mice, Inbred BALB C
;
Mycobacterium tuberculosis
;
immunology
;
Protein Kinases
;
genetics
;
immunology
;
Recombinant Proteins
;
immunology
;
T-Lymphocyte Subsets
;
immunology
;
Tuberculosis
;
prevention & control
;
Vaccination
;
Vaccines, Synthetic
;
immunology
10.Expression of verocytotoxic Escherichia coli antigens in tobacco seeds and evaluation of gut immunity after oral administration in mouse model.
Luciana ROSSI ; Alessia DI GIANCAMILLO ; Serena REGGI ; Cinzia DOMENEGHINI ; Antonella BALDI ; Vittorio SALA ; Vittorio DELL'ORTO ; Annelies CODDENS ; Eric COX ; Corrado FOGHER
Journal of Veterinary Science 2013;14(3):263-270
Verocytotoxic Escherichia (E.) coli strains are responsible for swine oedema disease, which is an enterotoxaemia that causes economic losses in the pig industry. The production of a vaccine for oral administration in transgenic seeds could be an efficient system to stimulate local immunity. This study was conducted to transform tobacco plants for the seed-specific expression of antigenic proteins from a porcine verocytotoxic E. coli strain. Parameters related to an immunological response and possible adverse effects on the oral administration of obtained tobacco seeds were evaluated in a mouse model. Tobacco was transformed via Agrobacteium tumefaciens with chimeric constructs containing structural parts of the major subunit FedA of the F18 adhesive fimbriae and VT2e B-subunit genes under control of a seed specific GLOB promoter. We showed that the foreign Vt2e-B and F18 genes were stably accumulated in storage tissue by the immunostaining method. In addition, Balb-C mice receiving transgenic tobacco seeds via the oral route showed a significant increase in IgA-positive plasma cell presence in tunica propria when compared to the control group with no observed adverse effects. Our findings encourage future studies focusing on swine for evaluation of the protective effects of transformed tobacco seeds against E. coli infection.
Administration, Oral
;
Agrobacterium tumefaciens
;
Animals
;
Antigens, Bacterial/genetics/metabolism
;
Bacterial Vaccines/administration & dosage/adverse effects/*pharmacology
;
Edema Disease of Swine/*immunology/microbiology
;
Escherichia coli Infections/immunology/microbiology/*veterinary
;
Escherichia coli Proteins/*genetics/metabolism
;
Female
;
Fimbriae Proteins/genetics/metabolism
;
Genetic Engineering
;
Intestines/immunology/microbiology/pathology
;
Mice
;
Mice, Inbred BALB C
;
Models, Animal
;
Plants, Genetically Modified/*genetics/metabolism
;
Seeds/genetics/metabolism
;
Shiga Toxin 2/genetics/metabolism
;
Shiga-Toxigenic Escherichia coli/genetics/immunology/*pathogenicity
;
Swine
;
Tobacco/*genetics/metabolism
;
Virulence Factors/genetics/metabolism

Result Analysis
Print
Save
E-mail